To the Editor-Irreplaceable antiarrhythmic medications are disappearing: the case of quinidine

Heart Rhythm

Volumn 7, Issue 6, 2010, Pages 863-

  Viskin, Sami ^a   Belhassen, Bernard ^a   Wilde, Arthur A ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; QUINIDINE;

BRUGADA SYNDROME; DEFIBRILLATOR; DRUG INDUSTRY; DRUG MARKETING; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; LETTER; PRIMARY PREVENTION; PRIORITY JOURNAL; SUDDEN DEATH;

ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; DRUG INDUSTRY; HUMANS; QUINIDINE;

EID: 77952525575     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2010.03.011     Document Type: Letter

References (5)

1. Haissaguerre M., Derval N., Sacher F., et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 358 (2008) 2016-2023
2. Ohgo T., Okamura H., Noda T., et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 4 (2007) 695-700
3. Viskin S., Antzelevitch C., Marquez M.F., and Belhassen B. Quinidine: a valuable medication joins the list of "endangered species.". Europace 9 (2007) 1105-1106
4. Viskin S., Wilde A.A., Tan H.L., Antzelevitch C., Shimizu W., and Belhassen B. Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm 6 (2009) 401-404
5. Wilde A.A., and Langendijk P. Antiarrhythmic drugs, patients, and the pharmaceutical industry: value for patients, physicians, pharmacists or shareholders?. Neth Heart J 15 (2007) 127-128